NEWS

  • CEMM IDENTIFIES INHERITED SUSCEPTIBILITY FOR A BLOOD MALIGNANCY

    Important discovery at the Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM): In cooperation with the Medical University of Vienna, CeMM scientists show that a common gene variant increases the risk of developing a certain type of blood malignancy. Carriers of the discovered gene variant are up to 6-fold more likely to… Read More »CEMM IDENTIFIES INHERITED SUSCEPTIBILITY FOR A BLOOD MALIGNANCY

    READ MORE

    SEEKING PATIENTS FOR FAMILIAL MPN STUDY

    MPN Research Foundation grantees Ben Ebert and Ann Mullally of Brigham & Women’s Hospital, Harvard Medical School have been studying the causes of familial MPN. These investigators are trying to determine the inherited, genetic basis for the development of MPN in multiple members of some families. They are using whole genome sequencing technologies in this… Read More »SEEKING PATIENTS FOR FAMILIAL MPN STUDY

    READ MORE

    WATCH THE WEST PALM BEACH PATIENT SYMPOSIUM PRESENTATIONS

    On January 10 the MPN Research Foundation hosted a small patient symposium in West Palm Beach, Florida. While we were unable to provide a webcast for the event, we do have the powerpoint presentations of each speaker. You may view each presentation below. Dr. Robert Jacobson, Palm Beach Cancer Institute: Forty Year Overview of MPNs Dr.… Read More »WATCH THE WEST PALM BEACH PATIENT SYMPOSIUM PRESENTATIONS

    READ MORE

    CYTOPIA APPOINTS STUDY CHAIRMAN FOR JAK2 CLINICAL TRIAL

    Pharmalive.com, July 30, 2008 – Dr Tefferi is a world-renowned expert in the treatment of myeloproliferative disorders (MPDs) and has authored over 500 research publications and given many hundreds of invited lectures in haematology. He also serves on the editorial boards of a number of leading haematology journals. Myelofibrosis patients suffer a bone marrow disorder… Read More »CYTOPIA APPOINTS STUDY CHAIRMAN FOR JAK2 CLINICAL TRIAL

    READ MORE

    REQUEST FOR PROPOSALS

    We are not currently accepting applications. Research Alliance Year 4 (2008) Criteria and Application info Please see the links above for details on each program. Both the Intent Letter and Full Proposal should be emailed to the attention of Michelle Woehrle at mwoehrle@MPNResearchFoundation.org CRITERIA FOR EVALUATION Proposals will be reviewed by the MPD Foundation’s Scientific Advisory… Read More »REQUEST FOR PROPOSALS

    READ MORE

    UCSD, TARGEGEN TEAM-UP ON BLOOD DISEASE TREATMENT

    By Terri Somers Union-Tribune Staff Writer 9:01 a.m. April 7, 2008 A one-year scientific collaboration that included the University of California San Diego and the tiny local biotechnology company TargeGen has moved a treatment for a potentially fatal blood disease into human trials at record speed. The experimental drug is also the first in clinical… Read More »UCSD, TARGEGEN TEAM-UP ON BLOOD DISEASE TREATMENT

    READ MORE

    INCYTE REPORTS PROGRESS IN MULTIPLE CLINICAL PROGRAMS AND EXPANDS JAK INHIBITOR PROGRAM

    Wilmington, Del. — (Business Wire) — Incyte Corporation (Nasdaq: INCY) today reported full year and fourth quarter 2007 financial results, and announced its 2008 financial guidance and key objectives and plans for its rapidly expanding clinical pipeline. Paul A. Friedman, M.D., President and CEO of Incyte, state, “Over the past year, we’ve worked intensively to… Read More »INCYTE REPORTS PROGRESS IN MULTIPLE CLINICAL PROGRAMS AND EXPANDS JAK INHIBITOR PROGRAM

    READ MORE

    CYTOPIA NOMINATES JAK2 CLINICAL CANDIDATE FOR MYELOPROLIFERATIVE DISORDERS

    03/18/2008 Cytopia Limited (ASX:CYT) has selected CYT387, a selective and potent JAK2 inhibitor, for formal preclinical development to treat myeloproliferative disorders (MPDs). This follows extensive laboratory experimentation and includes the recent demonstration of activity in an in-vivo model of myeloproliferative disease. Myeloproliferative disorders are a group of diseases including myelofibrosis, polycythemia vera (PV) and essential… Read More »CYTOPIA NOMINATES JAK2 CLINICAL CANDIDATE FOR MYELOPROLIFERATIVE DISORDERS

    READ MORE

    TARGEGEN ANNOUNCES INITIATION OF CLINICAL TRIAL OF JAK2 INHIBITOR TG101348 IN MYELOPROLIFERATIVE DISEASE PATIENTS

    San Diego, CA – January 31, 2008 – TargeGen, Inc. today announced that the Company has started a multi-center Phase I/II clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myeloproliferative diseases. The V617F mutation of JAK2 is implicated in the pathogenesis of certain myeloproliferative diseases, including polycythemia… Read More »TARGEGEN ANNOUNCES INITIATION OF CLINICAL TRIAL OF JAK2 INHIBITOR TG101348 IN MYELOPROLIFERATIVE DISEASE PATIENTS

    READ MORE

    JAK2 INHIBITOR SHOWS POTENT ACTIVITY IN CELLS FROM MPD PATIENTS

    MELBOURNE, Australia, Jan. 30 /PRNewswire/ — Australian and New York based company Cytopia Limited announced today that its lead JAK2 inhibitor compound CYT387 has demonstrated potent activity in cells isolated from patients with myeloproliferative disorders (MPDs). MPDs are a series of diseases where there is over-production of particular cells within the blood stream. One of… Read More »JAK2 INHIBITOR SHOWS POTENT ACTIVITY IN CELLS FROM MPD PATIENTS

    READ MORE

    1 35 36 37 38 39
  • Get updates on MPN patients and research breakthroughs.
    What are the latest developments in MPN Research?